Inactive matrix Gla protein is elevated in patients with inflammatory bowel disease

Figure 1 Plasma dephosphorylated and uncarboxylated matrix Gla protein levels in inflammatory bowel disease patients and control group (A) and between patients with Crohn’s disease and ulcerative colitis (B). ^aP < 0.001 vs control group; ^bP = 0.432 vs ulcerative colitis group. dp-ucMGP: Dephosphorylated and uncarboxylated matrix Gla protein.

Figure 2 Correlation analysis between plasma dephosphorylated and uncarboxylated matrix Gla protein levels and fecal calprotectin (A) and disease duration (B) in patients with inflammatory bowel disease (n = 70). ^aP < 0.001, r = 0.396; ^bP = 0.115, r = -0.190. dp-ucMGP: Dephosphorylated and uncarboxylated matrix Gla protein.

Figure 3 Correlation analysis between plasma dephosphorylated and uncarboxylated matrix Gla protein levels and age (A), body Mass Index (B) waist circumference (C) and hsCRP (D) in total study population (n = 130). ^aP = 0.016, r = 0.210; ^bP = 0.289, r = 0.094; ^cP = 0.002, r = 0.264; ^dP < 0.001, r = 0.477.

Figure 4 Dephosphorylated and uncarboxylated matrix Gla protein concentrations between tertiles of high sensitivity C-reactive protein (A) and FC levels (B). Tested with one-way analysis of variance with post hoc Sceffé test to examine differences between each of the groups; ^aP < 0.05 vs first hsCRP tertile; ^bP < 0.05 vs second hsCRP tertile ; ^cP < 0.05 vs first FC tertile; ^dP < 0.05 vs second FC tertile; hsCRP: High sensitivity C-reactive protein; FC: Fecal calprotectin.